388 related articles for article (PubMed ID: 14568972)
1. Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates: implications for vaccine development.
May RJ; Beenhouwer DO; Scharff MD
J Immunol; 2003 Nov; 171(9):4905-12. PubMed ID: 14568972
[TBL] [Abstract][Full Text] [Related]
2. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library.
Beenhouwer DO; May RJ; Valadon P; Scharff MD
J Immunol; 2002 Dec; 169(12):6992-9. PubMed ID: 12471134
[TBL] [Abstract][Full Text] [Related]
3. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection.
Fleuridor R; Lees A; Pirofski L
J Immunol; 2001 Jan; 166(2):1087-96. PubMed ID: 11145689
[TBL] [Abstract][Full Text] [Related]
4. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.
Casadevall A; Mukherjee J; Devi SJ; Schneerson R; Robbins JB; Scharff MD
J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327
[TBL] [Abstract][Full Text] [Related]
5. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z
Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223
[TBL] [Abstract][Full Text] [Related]
6. Unexpected diversity in the fine specificity of monoclonal antibodies that use the same V region gene to glucuronoxylomannan of Cryptococcus neoformans.
McFadden DC; Casadevall A
J Immunol; 2004 Mar; 172(6):3670-7. PubMed ID: 15004170
[TBL] [Abstract][Full Text] [Related]
7. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.
Zhang H; Zhong Z; Pirofski LA
Infect Immun; 1997 Apr; 65(4):1158-64. PubMed ID: 9119446
[TBL] [Abstract][Full Text] [Related]
8. The common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies.
Nakouzi A; Zhang T; Oscarson S; Casadevall A
Vaccine; 2009 Jun; 27(27):3513-8. PubMed ID: 19464529
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
Mukherjee J; Kozel TR; Casadevall A
J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures.
Oscarson S; Alpe M; Svahnberg P; Nakouzi A; Casadevall A
Vaccine; 2005 Jun; 23(30):3961-72. PubMed ID: 15917118
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans.
Brandt S; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Sep; 10(5):903-9. PubMed ID: 12965925
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.
Maitta RW; Datta K; Lees A; Belouski SS; Pirofski LA
Infect Immun; 2004 Jan; 72(1):196-208. PubMed ID: 14688097
[TBL] [Abstract][Full Text] [Related]
13. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.
Maitta RW; Datta K; Chang Q; Luo RX; Witover B; Subramaniam K; Pirofski LA
Infect Immun; 2004 Aug; 72(8):4810-8. PubMed ID: 15271943
[TBL] [Abstract][Full Text] [Related]
14. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.
Duro RM; Netski D; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Mar; 10(2):252-8. PubMed ID: 12626451
[TBL] [Abstract][Full Text] [Related]
15. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model.
Devi SJ
Vaccine; 1996 Jun; 14(9):841-4. PubMed ID: 8843625
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies.
Todaro-Luck F; Reiss E; Cherniak R; Kaufman L
Infect Immun; 1989 Dec; 57(12):3882-7. PubMed ID: 2680986
[TBL] [Abstract][Full Text] [Related]
17. Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens.
Pirofski LA
Trends Microbiol; 2001 Sep; 9(9):445-51. PubMed ID: 11553457
[TBL] [Abstract][Full Text] [Related]
18. Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide.
Valadon P; Nussbaum G; Oh J; Scharff MD
J Immunol; 1998 Aug; 161(4):1829-36. PubMed ID: 9712050
[TBL] [Abstract][Full Text] [Related]
19. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity.
Devi SJ; Schneerson R; Egan W; Ulrich TJ; Bryla D; Robbins JB; Bennett JE
Infect Immun; 1991 Oct; 59(10):3700-7. PubMed ID: 1716613
[TBL] [Abstract][Full Text] [Related]
20. Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice.
Nussbaum G; Anandasabapathy S; Mukherjee J; Fan M; Casadevall A; Scharff MD
Infect Immun; 1999 Sep; 67(9):4469-76. PubMed ID: 10456888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
